The Department of Veterans Affairs has begun enrolling veterans in its first ever clinical trial of therapy assisted by MDMA, the drug commonly known as Ecstasy, targeting those with severe, treatment resistant PTSD and alcohol use disorder. The study, which opened in May 2026, marks a cautious but meaningful step toward generating the rigorous evidence the FDA has demanded before it will reconsider approving the psychedelic for widespread use.
Approximately 80 veterans will take part in the randomized, placebo controlled trial across two sites: the Providence VA Medical Center in Rhode Island and the VA Connecticut Healthcare System in West Haven. Participants will receive either MDMA assisted therapy or an identical structured session using an active placebo, with neither patients nor clinicians knowing who received which. The double blind design directly addresses concerns the FDA raised in August 2024 when it declined to approve MDMA for PTSD, citing issues with prior trial design and durability of benefits. Results are expected in May 2030.
The trial focuses on veterans who have not responded to standard treatments including medication management, group therapy, prolonged exposure and cognitive processing therapy. Both severe PTSD and alcohol use disorder must be present, a dual diagnosis that is common among veterans but often poorly addressed. “Too often, alcohol use is treated as a separate behavioral failure instead of being understood as part of the PTSD picture,” said Benjamin Krause, a disabled Air Force veteran and attorney who works with veterans on complex benefits appeals. He noted that the trial reflects the real world complexity of veteran health far better than simplified research models.
What a Positive Result Would Mean and What Veterans Should Do Now
Even if the trial yields positive results, widespread access will take years. “This is not VA opening the door for widespread MDMA treatment,” Krause said. “It is VA testing whether this approach can be studied safely and credibly in a veteran population with complex needs.” A positive outcome would trigger further FDA review, possible DEA scheduling changes, provider training, site certification and integration with existing care programs. The broader VA psychedelic research initiative is supported by more than $23 million in external grants across 19 active studies, accelerated by a April 2026 executive order directing federal agencies to fast track psychedelic therapy research.
Krause urged veterans to avoid seeking MDMA through unregulated channels due to legal, medical and trauma risks. “Underground or overseas treatment may not include proper screening, emergency support, or coordination with existing providers,” he said. Instead, he advised veterans to speak with qualified medical professionals, keep treating providers informed and pursue lawful clinical trials when available. He also emphasized that documenting treatment failures and functional impairment remains important for disability claims, even while waiting for a clinical pathway to emerge.
The trial is a serious research step, not a shortcut to treatment. But for the tens of thousands of veterans who have exhausted standard options and continue to struggle, it represents a genuine effort to build credible evidence for a therapy many have long sought. “Veterans should be hopeful that VA is finally studying treatments that many have been asking about for years,” Krause said. “A positive trial would be a major step, but it would not be the finish line. It would start the next phase of turning research into a safe, lawful, scalable treatment model.”